Literature DB >> 3494608

Initial experience with SPECT of the brain using 99mTc-hexamethyl-propyleneamine oxime (99mTc-HM-PAO).

G Spreafico, F Cammelli, G Gadola, G Nicola, F Zancaner, G Tonnarelli, E Sala, R Freschi.   

Abstract

A recently developed 99mTc radiocompound, hexamethyl-propyleneamine oxime (99mTc-HM-PAO) exhibits favorable properties for regional cerebral tomograms in man utilizing conventional instrumentation (SPECT). Planar and tomographic studies using a rotating gamma camera equipped with a high sensitivity, low energy, collimator were performed in 5 normal subjects and 20 patients suffering from different cerebral diseases. SPECT abnormalities observed in patients with CVD, brain tumors and hydrocephalus were compared with results from X-ray CT. Our preliminary study demonstrates the feasibility of assessing regional brain perfusion using SPECT and a 99mTc radiopharmaceutical which is lipid soluble and has a high extraction fraction in the brain.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3494608     DOI： 10.1007/BF00296097

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  5 in total

1.  Cerebral blood flow tomography with xenon-133.

Authors:  N A Lassen
Journal:  Semin Nucl Med       Date:  1985-10       Impact factor: 4.446

Review 2.  Clinical brain imaging with isopropyl-iodoamphetamine and SPECT.

Authors:  H D Royal; T C Hill; B L Holman
Journal:  Semin Nucl Med       Date:  1985-10       Impact factor: 4.446

3.  Cerebral uptake and retention of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO).

Authors:  R A Holmes; S B Chaplin; K G Royston; T J Hoffman; W A Volkert; D P Nowotnik; L R Canning; S A Cumming; R C Harrison; B Higley
Journal:  Nucl Med Commun       Date:  1985-08       Impact factor: 1.690

4.  A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease.

Authors:  P J Ell; J M Hocknell; P H Jarritt; I Cullum; D Lui; D Campos-Costa; D P Nowotnik; R D Pickett; L R Canning; R D Neirinckx
Journal:  Nucl Med Commun       Date:  1985-08       Impact factor: 1.690

5.  Regional quantitative noninvasive assessment of cerebral perfusion and function with N-isopropyl-[123I]p-iodoamphetamine.

Authors:  G K von Schulthess; E Ketz; P A Schubiger; A Bekier
Journal:  J Nucl Med       Date:  1985-01       Impact factor: 10.057
  5 in total
  5 in total

1.  Brain perfusion with intracarotid injection of 99mTc-HM-PAO in partial epilepsy during amobarbital testing.

Authors:  S O Hietala; H Silfvenius; J Aasly; M Olivecrona; L Jonsson
Journal:  Eur J Nucl Med       Date:  1990

2.  A comparison of Tc-99m HM-PAO and I-123 IMP cerebral SPECT images in Alzheimer's disease and multi-infarct dementia.

Authors:  H G Gemmell; P F Sharp; J A Besson; K P Ebmeier; F W Smith
Journal:  Eur J Nucl Med       Date:  1988

3.  Comparative evaluation of SPECT, CT and CW Doppler data in patients with ischemic lesions of the brain.

Authors:  M Zanardi; M Rossi; M Bonamini; P Fiorio; M Caputo; A Manzara
Journal:  Ital J Neurol Sci       Date:  1991-08

4.  The behavior of 99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) in blood and brain.

Authors:  K Nakamura; Y Tukatani; A Kubo; S Hashimoto; Y Terayama; T Amano; F Goto
Journal:  Eur J Nucl Med       Date:  1989

5.  Initial experience with Tc-99m-HM-PAO in the study of brain tumors.

Authors:  J W Babich; F Keeling; M A Flower; L Repetto; A Whitton; S Fielding; A Fullbrook; R J Ott; V R McCready
Journal:  Eur J Nucl Med       Date:  1988
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.